1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2019, Issue 3
  5. Article
Volume 2019, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

The aim of this study was to determine the demographic, clinical, and immunological characteristics of patients with systemic sclerosis living in Qatar. This retrospective study included 42 patients with systemic sclerosis who attended Rheumatology Clinics at Hamad General Hospital in Doha, Qatar, between January 2000 and December 2014. All patients fulfilled the 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis. The 42 consecutively recruited patients of mixed ethnicities consisted of 37 (88.1%) females and 5 (11.9%) males. Of the total 42 patients, 22 (52.4%) had diffuse cutaneous systemic sclerosis (dcSSc) and 20 (47.6%) had limited cutaneous systemic sclerosis (lcSSc). Mean age at onset of first symptoms was 34.5 ± 12 years, and mean age at diagnosis was 36.1 ± 11.5 years. During follow-up, Raynaud's phenomenon occurred in 36 (85.7%) patients, sclerodactyly in 39 (92.9%) patients, digital ulcers in 16 (38.1%) patients, calcinosis in 6 (14.3%) patients, telangiectasia in 16 (38.1%) patients, and arthritis in 13 (31%) patients. The gastrointestinal and respiratory systems were the most frequently affected internal organs. Gastrointestinal involvement was present in 36 (85.7%) patients, and respiratory involvement was found in 30 (71.4%) patients. The majority of patients had positive antinuclear antibodies (ANA; 97.6%). Anti-Scl-70 antibody was found in 66.7% and anti-centromere antibody (ACA) was detected in 14.3% of the patients. To our knowledge, this is the first study that describes the clinical and immunological profile of patients with systemic sclerosis living in Qatar. This study cohort showed an earlier age of disease onset and diagnosis than that reported in other international studies. Furthermore, in contrast to several other studies, the diffuse type of scleroderma was more commonly observed than the limited type, which resulted in a high frequency of anti-Scl-70 antibody and interstitial lung disease.

© 2019 Alam, Abdulaziz, Ul Haq, Mahdy, Mohammed Siam, Chandra, Al Emadi, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2019.16
2019-12-24
2024-11-10
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2019/3/qmj.2019.16.html?itemId=/content/journals/10.5339/qmj.2019.16&mimeType=html&fmt=ahah

References

  1. Balbir-Gurman A, Braun-Moscovici Y. Scleroderma: new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012; 26:1:13–24.
     [Google Scholar]
  2. Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol. 2010; 24:6:857–869.
     [Google Scholar]
  3. Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol. 2011; 38:11:2406–2409.
     [Google Scholar]
  4. Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010; 24:3:387–400.
     [Google Scholar]
  5. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol. 2004; 16:6:718–722.
     [Google Scholar]
  6. Kirby DF, Chatterjee S. Evaluation and management of gastrointestinal manifestations in scleroderma. Curr Opin Rheumatol. 2014; 26:6:621–629.
     [Google Scholar]
  7. Antoniou K, Wells A. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008; 20:6:686–691.
     [Google Scholar]
  8. Fan MH, Feghali-Bostwick CA, Silver RM. Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol. 2014; 26:6:630–636.
     [Google Scholar]
  9. Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012; 24:6:669–676.
     [Google Scholar]
  10. Parks JL, Taylor MH, Parks LP, Silver RM. Systemic sclerosis and the heart. Rheum Dis Clin North Am. 2014; 40:1:87–102.
     [Google Scholar]
  11. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005; 35:1:35–42.
     [Google Scholar]
  12. Skare TL, Fonseca AE, Luciano AC, Azevedo PM. Autoantibodies in scleroderma and their association with the clinical profile of the disease: A study of 66 patients from southern Brazil. An Bras Dermatol. 2011; 86:6:1075–1081.
     [Google Scholar]
  13. Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014; 26:6:646–652.
     [Google Scholar]
  14. Qaradakhy TA, Ali KM, Karim OH. Prevalence of interstitial lung disease among patients with systemic sclerosis in Iraqi Kurdistan. Arthritis Res Ther. 2012; 14:1:P13.
     [Google Scholar]
  15. Moneim GA, Darweesh HEA, Ismael M, Raafat S. Frequency of disease subsets and patterns of organ involvement among Egyptian patients with systemic sclerosis -A retrospective study. Egypt Rheumatol. 2013; 35:3:145–149.
     [Google Scholar]
  16. Poormoghim H, Moghadam AS, Moradi-Lakeh M, Jafarzadeh M, Asadifar B, Ghelman M, et al.  Systemic sclerosis: Demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int. 2013; 33:8:1943–1950.
     [Google Scholar]
  17. Pradhan V, Rajadhyaksha A, Nadkar M, Pandit P, Surve P, Lecerf M, et al.  Clinical and autoimmune profile of scleroderma patients from Western India. Int J Rheumatol. 2014;:6.
     [Google Scholar]
  18. Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, et al.  Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis. 2015; 18:4:459–465.
     [Google Scholar]
  19. Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol. 2012; 22:2:272–279.
     [Google Scholar]
  20. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al.  Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum. 2012; 41:6:789–800.
     [Google Scholar]
/content/journals/10.5339/qmj.2019.16
Loading
Characteristics of patients with systemic sclerosis living in Qatar
Qatar Medical Journal 2019, 16 (2020); https://doi.org/10.5339/qmj.2019.16
/content/journals/10.5339/qmj.2019.16
/content/journals/10.5339/qmj.2019.16
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): anti-centromere antibody, anti-Scl-70 antibody, antinuclear antibodies, diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error